Çö±âÁõ ÇϳªÀÇ¿ø ÇǺÎÁ¡¸·¾ÈÁõÈıº °ïÁö¸§ Ä¡¾Æ »ï¼º¾È°ú ´ëÀå¾Ï ±Ý¿¬ ¼­¿ï°¡Á¤ÀÇÇаúÀÇ¿ø »çÁø °¡Æò ÇѾ౹ À£Ä¡°úÀÇ¿ø Á¤½Å°Ç°­ÀÇÇаú ¼Ò¾ÆÁ¶¾Ø¹ÚºäƼÀÇ¿ø ³ÖÀ¸¸é ´É·ÂÀÌ ÀÌ¿ëÂù º¹½Ì

¿¬¼ö°­ÁÂ
2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-03-23

2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-03-23
±³À°ÀÏÀÚ : 2024-03-23
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£

±³À°ÁÖÁ¦ : 2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­ÁÂ

ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ¿ï°æÁöȸ

´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 051-240-5070

À̸ÞÀÏ : sericonf@gmail.com

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í 1. »çÀüµî·Ï 30,000ÇöÀåµî·Ï 50,000  2. Æò»ýȸ¿øÀº »çÀüµî·Ïºñ ¹«·áÀÔ´Ï´Ù. Æò»ýȸ¿ø °¡ÀÔÀ» ¿øÇϽô ȸ¿øÀº 10¸¸¿ø ÀÔ±ÝÈÄ ÇÐȸ·Î ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:00~09:20 Major imaging trials for coronary intervention in 2023 ÃÖÁ¤Ãµ(ºÎ»ê´ëÇб³º´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:20~09:40 How to de-escalate the antiplatelet in patients at high bleeding risk °­¹Î±Ô(ÁøÁÖ°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:40~10:00 Calcification: Final enemy for coronary intervention, How to deal with? ÀåÀç½Ä(ºÎ»ê¹éº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:00~10:20 Discussion ÀÌ¿ëȯ,ÇѾçõ,¼ÛÀ±¼®,¹Ú¿ëÈÖ(µ¿·¡ºÀ»ýº´¿ø,â¿øÆÄƼ¸¶º´¿ø,ÇØ¿î´ë¹éº´¿ø,â¿ø°æ»ó´ëº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:20~10:30 ½Ä»ç ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:30~10:50 Evaluaion and treatemnt of resistant hypertension ¼­Á¤¼÷(ºÎ»ê´ë¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:50~11:10 Obesity and GLP-1 antagonist ±è°èȯ(°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:10~11:30 Appraoch and treatment for moderate AS ¹Ú¿ëÇö(¾ç»êºÎ»ê´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:30~11:50 Discussion À̼ö¿ë,ÀåÁ¤À±,Á¶À±¼º,À¯Á¤³²(¾ç»êºÎ»ê´ëº´¿ø,â¿ø°æ»ó´ëº´¿ø.ÇØ¿î´ë¹éº´¿ø.ÇØ¿î´ë¹éº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:50~12:00 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:10~12:30 A new stratetgy of lipid lowering therapy in ACS ±è¼öÈ«(ºÎ»êº¸Èƺ´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:30~12:50 ARNI for heart failure across the range of ejection fraction ÃÖÁ¤Çö(ºÎ»ê´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:50~13:10 Discussion ±è¼º¸¸,±è¼öÇü,ÇãÁ¤È£,±è¹Î¿õ.Ȳ¼®Àç(µ¿ÀÇÀÇ·á¿ø,´ëµ¿º´¿ø,°í½Å´ëº´¿ø.â¿øÇѸ¶À½º´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:10~13:30 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:30~13:50 AF ablation in HFrEF and HFpEF ±è±âÈÆ(ºÎ»ê¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:50~14:10 NOAC: clinial recommendations for Asian population À¯°¡ÀÎ(â¿ø°æ»ó´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 14:10~14:30 PVC assessment and management °ûÇýºó(»ï¼ºÃ¢¿ø´ëº´¿ø)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 312È£ 14:30~14:50 Discussion ¹Ú¿µ¾Æ,¹ÚÁ¾¼º,±èÇý¸®,ÀÓ¼ºÀÏ(ºÎ»ê¹éº´¿ø,µ¿¾Æ´ëº´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø.°í½Å´ëº¹À½º´¿ø)

ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 313È£ 14:50~15:00 Break ()

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 314È£ 15:00~15:25 TAVR device selection: Which valve to whom ¿ÀÁØÇõ(ºÎ»ê´ëº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 315È£ 15:25~15:50 TAVR for bicuspid AV and AR ¾çÅÂÇö(ºÎ»ê¹éº´¿ø)

±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 316È£ 15:50~16:20 LAA closure: When and how? ±èÁß¼±(½ÅÃ̼¼ºê¶õ½º)

Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 317È£ 16:20~16:40 Discussion ¹Ú»ó¿ì,Á¶¿ë¶ô,À̽ÿø,ÁøÇÑ¿µ(¿ï»ê´ëº´¿ø.µ¿¾Æ´ëº´¿ø,ÇѼ­º´¿ø,ºÎ»ê¹éº´¿ø)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 17,782 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 17,487 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 17,141 , ´ñ±Û¼ö : 0

[¼­¿ï] ½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (1ÀÏÂ÷) : 2024-04..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : Conrad Hotel Seoul (5F PARK BALLROOM) ±³À°ÁÖÁ¦ : 2024 7th APCMS (Asia-Pacific

Ãßõ¼ö : 0 , Á¶È¸¼ö : 18,220 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 16,642 , ´ñ±Û¼ö : 0